

# NEWS RELEASE



November 10, 2021

## **Nippon Shinyaku enter into an Option Agreement for DYN101 in Japan**

KYOTO, Japan, November 10, 2021 - Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, President: Toru Nakai) announced today that Nippon Shinyaku and Dynacure (Headquarters: Strasbourg, CEO: Stéphane van Rooijen) has entered into an option agreement for the development and commercialization of DYN101 in the territory of Japan. Under the terms of the agreement, Nippon Shinyaku has secured opt-in rights to exclusively pursue the development and commercialization of DYN101 in Japan depending on analysis of interim data from the Phase 1/2 study, UNITE-CNM.

Centronuclear Myopathies (CNM) are an intractable, rare disorder that are characterized by muscle weakness from birth or infancy due to congenital structural abnormalities of skeletal muscle. Since there is currently no specific therapy for CNM without symptomatic treatments such as artificial respiration assistance and supportive care, new therapeutic agents are desired.

DYN101, an investigational antisense oligonucleotide product candidate, is designed to reduce the expression of dynamin 2 protein (DNM2) whose mutation is one of the cause of CNM, and is currently being evaluated in a Phase 1/2 clinical trial, UNITE-CNM, at multiple clinical sites in Europe. DYN101 has been granted orphan drug designation by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and rare pediatric disease designation by the FDA.

Nippon Shinyaku is focusing on the field of intractable, rare disorders. According to this agreement on DYN101, Nippon Shinyaku aims to contribute to the treatment for patients suffering from CNM.

**About Nippon Shinyaku**

Our mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, we aim to be an organization trusted by the community. Please visit our website (<http://www.nippon-shinyaku.co.jp/english/>) for products or detailed information.

**About Dynacure**

Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drug candidates. For more information, please visit [www.dynacure.com](http://www.dynacure.com).

**Contact**

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.

FAX: +81-75-321-9128